Breaking Finance News

RA Pharmaceuticals (NASDAQ:RARX) target price raised to $21.00, reported today by RBC Capital

RA Pharmaceuticals (NASDAQ:RARX) had its target price raised to $21.00 by RBC Capital in a report released 09/15/2017. The new target price indicates a possible upside of 0.41% based on the company's last stock close price.

Yesterday RA Pharmaceuticals (NASDAQ:RARX) traded 2.37% higher at $14.87. The company’s 50-day moving average is $14.33 and its 200-day moving average is $17.93. The last stock close price is down -15.61% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time. 64,252 shares of the stock were exchanged, down from an average trading volume of 109,225

See Chart Below

RA Pharmaceuticals (NASDAQ:RARX)

RA Pharmaceuticals has a 52 week low of $12.05 and a 52 week high of $24.12 RARX’s total market value is presently $0.

Brief Synopsis About RA Pharmaceuticals (NASDAQ:RARX)

Ra Pharmaceuticals, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade. It has leveraged the Extreme Diversity peptide chemistry platform to develop a portfolio of products that selectively inhibit the complement system and other immune targets. Its main program, RA101495, is a macrocyclic peptide inhibitor of complement component 5 (C5), which is in Phase I stage of development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). RA101495 binds a site on the C5 protein to inhibit cleavage into C5a and C5b, thereby preventing red blood cell lysis by inhibiting the production and assembly of the membrane attack complex (MAC). RA101495 is being developed as an alternative to eculizumab therapy for patients with PNH.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.